123 completed, 37 unknown, 25 terminated, 19 recruiting. 224 Phase 2, 38 Phase 1, 7 Phase 3.
Follow Ifosfamide: new trials by email Literature Review of Ifosfamide trials Research Report on Ifosfamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
| A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Metastasis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2026-03-11 | 2026-03-17 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) Doxorubicin, Ifosfamide, Dacarbazine - Sarcoma,Soft Tissue | Phase 2 | Recruiting | Swiss Cancer Institute | 24 | 2025-10-27 | 2025-12-30 |
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma JS203 in combination with gemcitabine and oxaliplatin, JS203 in combination with ifosfamide, carboplatin and etoposide, JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone - B-cell Non-Hodgkin's Lymphoma | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 180 | 2025-08-17 | 2026-09-04 |
| Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of California, Davis | 25 | 2025-07-31 | 2026-06-30 |
| Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma Envafolimab combined with an AI regimen (doxorubicin and ifosfamide) - Soft Tissue Sarcoma | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2024-09-30 | 2026-04-24 |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma DANYELZA, Sargramostim, Cytoxan - High-risk Neuroblastoma, Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2024-07-22 | 2026-08-28 |
| TIP Regimen Combined With Toripalimab Neoadjuvant Therapy for Locally Advanced Penile Cancer Paclitaxel + Ifosfamide + Cisplatin & Toripalimab - Penile Cancer | Phase 2 | Completed | Sun Yat-sen University | 25 | 2024-05-31 | 2026-10-13 |
| Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL Linperlisib, Rituximab, Gemcitabine - Relapsed/Refractory Large B-Cell Lymphoma | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 89 | 2024-05-28 | 2024-07-08 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Samsung Medical Center | 37 | 2024-05-01 | 2026-04-23 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Carboplatin - Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Active not recruiting | David Bond, MD | 37 | 2023-06-29 | 2026-07-20 |
| A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma Sulfatinib, Etoposide, Isophosphamide - Osteosarcoma | Phase 1 / Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 148 | 2023-01-01 | 2022-10-21 |
| Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO) Doxorubicin, Ifosfamide, INCMGA00012 - Resectable Sarcoma | Phase 2 | Active not recruiting | Institut BergoniƩ | 66 | 2022-12-07 | 2026-10-08 |
| A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Obinutuzumab, Glofitamab, Rituximab - Mature B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 65 | 2022-11-16 | 2026-11-05 |
| Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma Pembrolizumab, Rituximab, Ifosfamide - Diffuse Large B Cell Lymphoma | Phase 2 | Active not recruiting | University of Southampton | 65 | 2022-06-27 | 2026-05-15 |
Showing 20 of 224. Sign in to see all of them.
Sarcoma (45) · Lymphoma (44) · Lymphoma, Large B-Cell, Diffuse (37) · Lymphoma, Non-Hodgkin (26) · Osteosarcoma (21) · Hodgkin Disease (20) · Burkitt Lymphoma (19) · Testicular Neoplasms (16) · Lymphoma, Follicular (13) · Ovarian Neoplasms (13) · Recurrence (13) · Lymphoma, Large-Cell, Immunoblastic (11) · Lymphoma, Mantle-Cell (11) · Testicular Germ Cell Tumor (11) · Leukemia (10)
Memorial Sloan Kettering Cancer Center (24) · National Cancer Institute (NCI) (14) · M.D. Anderson Cancer Center (12) · Children's Oncology Group (11) · Samsung Medical Center (7) · City of Hope Medical Center (6) · St. Jude Children's Research Hospital (6) · Northwestern University (4) · Sun Yat-sen University (4) · Cancer Research UK (3) · Dana-Farber Cancer Institute (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (3) · Italian Sarcoma Group (3) · Radiation Therapy Oncology Group (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)
United States (137) · Australia (21) · France (19) · Canada (18) · Italy (18) · United Kingdom (18) · China (15) · South Korea (12) · Germany (11) · Netherlands (10) · New Zealand (10) · Spain (10) · Puerto Rico (9) · Belgium (8) · Switzerland (8)
Craig Moskowitz, MD (7) · Darren Feldman, MD (3) · Ki Woong Sung, MD, PhD (3) · Alex F Herrera (2) · Armando Santoro, MD (2) · Dean F. Bajorin, MD (2) · Izidore S. Lossos, MD (2) · Lawrence D. Kaplan, MD (2) · Lisa Licitra, MD (2) · Marco Benazzo, MD (2) · Piero Nicolai, MD (2) · Robert J. Motzer, MD (2) · Tanya Trippett, MD (2) · A. McMillan (1) · Aaron R Weiss (1)
PMID 31401903, PMID 31545689, PMID 32827353, PMID 33735476, PMID 34416158, PMID 38271621, PMID 11600602, PMID 11904735, PMID 14739217, PMID 15042678, PMID 15999102, PMID 16204011, PMID 16382125, PMID 16446334, PMID 16500907, PMID 16826357, PMID 17075123, PMID 17194908, PMID 18612102, PMID 19338063, PMID 19636012, PMID 19767508, PMID 19994492, PMID 20038221, PMID 20194867, PMID 20338746, PMID 20572040, PMID 20625118, PMID 20715156, PMID 20855800, PMID 2156418, PMID 22055846, PMID 22184409, PMID 22251554, PMID 22282683, PMID 23065953, PMID 23242601, PMID 24028306, PMID 24146219, PMID 24428673, PMID 24595454, PMID 24637635, PMID 24894084, PMID 24957163, PMID 25651427, PMID 25833390, PMID 25957391, PMID 26199392, PMID 27465021, PMID 27544129
U10CA098543 (12), U10CA180886 (7), P30CA033572 (5), 2023 (2), P30CA015083 (2), P30CA015704 (2), P30CA016672 (2), P30CA060553 (2), U10CA031946 (2), 2015 (1), 2016 (1), 2018 (1), 2019 (1), K12CA086913 (1), N01CM62201 (1)